Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 211-219

  Breddin, H K ^a,b   Lippold, R ^a,b   Bittner, M ^a,b   Kirchmaier, C M ^a,b   Krzywanek, H J ^a,b   Michaelis, J ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Arterial occlusions; Fibrinogen; Healthy volunteers; Hemostaseological parameters; Predictive risk factors; Spontaneous platelet aggregation

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL OCCLUSION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033010986     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00056-8     Document Type: Article

References (65)

1. Pilgeram LO. Relation of plasma fibrinogen concentration changes to human arteriosclerosis. J Appl Physiolog 1961;16:660-4.
2. Banerjee AK, Pearson J, Gilliland EL, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostas 1992:68:261-3.
3. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT-Study: haemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 1992:12:1063-9.
4. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler Thromb 1994;14:54-9.
5. Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M. Platelet size, fibrinogen and lipoprotein (a) in coronary heart disease. Coron Artery Dis 1995;6:397-402.
6. Barasch E, Benderly M, Graff E, et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol 1995:48:757-65.
7. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl J Med 1984;311:501-4.
8. Stone MC, Thorpe JM. Plasma fibrinogen a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
9. Gallino A, Haeberli A, Baur HR, Straub PW. Fibrin formatio and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 1985;72:27-30.
10. Kannel WB, Wolf PA, Castelli WP, Agostino RB. Fibrinogen and risk of cardiovascular disease, the Framingham Study. J Am Med Assoc 1987;258:1183-6.
11. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987:114:413-9.
12. Wilson PWF, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 1987;59:91G-94.
13. Yarnell WG, Baker AJ, Sweetnam MP, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Study. Circulation 1991;83:836-44.
14. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991:91:191-205.
15. Nissinen A, Tervahauta M, Pekkanen J, et al. Prevalence and change of cardiovascular risk factors among men born 1900-19: the Finnish Cohorts of the Seven Countries Study. Age Ageing 1993:22:365-76.
16. Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women results from the Gotebog MONICA survey 1985. Ann Epidemiol 1994;4:369-74.
17. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. J Int Med 1996:239:499-507.
18. Sharp DS, Abbott RD, Burchfiel CM, et al. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vase Biol 1996;16:262-86.
19. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
20. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995;332:635-41.
21. Assmann G, Schulte H. Identification of individuals at high risk myocardial infarction. Atherosclerosis 1994;110:511-21.
22. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history. The Scottish Heart Health Study. Br Heart J 1993:69:338-42.
23. Christe M, Delley A, Marbet DA, Biland L, Duckert F. Fibrinogen, factor VIII related antigen, antithrombin III and 2-antiplasmin in peripheral arterial disease. Thromb Haemostas 1984:52:240-2.
24. Meade TW, Brozovic M, Chakrabarti RR, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
25. Yamanishi J, Sano H, Saito K, Furuta Y, Fukuzaki H. Plasma concentrations of platelet-specific proteins in different stages of essential hypertension: interactions between platelet aggregation, blood lipids and age. Thromb Haemostas 1985;54:539-43.
26. Zahavi J, Zahavi M. Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. Thromb Haemostas 1985;53:105-9.
27. Jäger E, Sinzinger H, Widhalm K, Kaliman J, Höfer R. Thrombozytenhalblebenszeit bei Patienten mit primärer Hyperlipidämic vom Typ Ha, lib und IV nach Fredrickson mit und ohne klinische Zeichen der Atherosklerose. Wien Klin Wschr 1992:94:421-5.
28. Popadic M, Haracic M, Rezacovic DE, Pirnat L. Circulating platelet aggregates in patients with coronary heart disease and lower limb ischemia. VASA 1985;14:35-37.
29. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991:84:613-7.
30. Sharp DS, Bath PMW, Martin JF, Beswick AD, Sweetnam PM. Platelet and erythrocyte volume and count: epidemiological predictors of impedance measured ADP-induced platelet aggregation in whole blood. Platelets 1994;5:252-7.
31. Hoogendijk EMG, Jenkins CSP, van Wijk EM, Jos J, Ten Cate JW. Spontaneous platelet aggregation in cerebrovascular disease II. Thromb Haemostas 1979;41:512-22.
32. McGill DA, Ardlie NG. Abnormal platelet reactivity in men with premature coronary heart disease. Coron Artery Dis 1994:5:889-900.
33. De Lorgeril M, Dureau G, Boissonnat P, et al. Platelet function and composition in heart transplant recipients compared with nontransplant coronary patients. Arterioscler Thromb 1992:12:222-30.
34. Breddin HK, Krzywanek HJ, Althoff P, et al. Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Int Angiol 1986;5:181-95.
35. Breddin HK. Über die gesteigerte Thrombozytenagglutination bei Gefäßkrankheiten. Schweiz Med Wschr 1965;95:655-60.
36. Breddin HK, Grun H, Krzywanek HJ, Schremmer W. On the measurement of spontaneous platelet aggregation. The platelet aggregation test III. Thromb Haemostas 1976;35:669-91.
37. Krzywanek HJ. Klinische Bedeutung der Thrombozytenfunktions-diagnostik. Stuttgart: Fischer, 1987.
38. Krzywanek HJ, Breddin K. Further evidence that enhanced spontaneous platelet aggregation is a risk factor in the occurrence of thromboembolic complications in vascular disease. Excerpta Med Int Congr Ser 1974;357:354-60.
39. Breddin HK, Grun H, Ziemen M, Bauer M, Krzywanek HJ. Factors influencing spontaneous and induced platelet aggregation. Studies with a new aggregometer. Excerpta Med Int Congr Ser 1974;357:302-14.
40. Michaelis J, Lippold R, Nafe B, Scheidt E. Risk assessment of future myocardial infarction from automated serial ECG analysis. J Electrocardiol 1992;25:20-5.
41. Michaelis J, Lippold R, Nafe B, Scheidt E. Prediction of future myocardial infarction from automated serial ECG analysis. In: Lun KC, et al., editors. Medinfo 92. Amsterdam: North Holland, 1992:852-7.
42. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
43. O'Brien JR, Etherington M, Jamieson S, Lawford P, Sussex J, Lincoln SV. Heparin neutralizing activity test in the diagnosis of acute myocardial infarction. J Clin Pathol 1975;28:975-9.
44. Thompson SG, Duckert F, Haverkate F, Thomson JM. The measurement of haemostatic factors in 16 European laboratories: quality assessment for the multicentre ECAT Angina Pectoris Study. Thromb Haemostas 1989;61:301-6.
45. Kovacs I, Ratnatunga CP, Ridler CD, Görög P, Edmonson SJ, Rees GM. Significance of plasma fibrinogen in coronary arterial disease: marker or causative risk factor for arterial thrombosis? Int J Cardiol 1992;35:57-64.
46. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldhourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. Atheroscler Thromb Vase Biol 1996;16:351-6.
47. Siegert G, Bergmann S, Jaross W, Assmann G. Abhängigkeit der Hämostaseparameter Fibrinogen, Plasminogenaktivator Inhibitor und Antithrombin III von Alter und Geschlecht sowie ihre Beziehung zu bekannten Risikofaktoren der Atherosklerose in der Bevölkerung von Dresden und Umgebung (DRECAN-Studie). Klin Labor 1992;38:499-505.
48. Balleisen L, Baily J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemostas 1985;54:475-9.
49. Conlan MG, Folsom AR, Finch A, et al. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemostas 1994;72:551-6.
50. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo J. For the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995;332:635-41.
51. Baker IA, Eastham R, Elwood PC, Etherington M, O'Brien JR, Sweetnam PM. Hemostatic factors associated with ischemic heart disease in men aged 45 to 64 years. The Speedwell Study. Br Heart J 1982;47:490-4.
52. Cooper J, Douglas AS. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis 1991;5:105-8.
53. Resch KL, Ernst E, Matrai A, Paulsen HE. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Int Med 1992;117:371-5.
54. Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Göteborg MONICA Survey 1985. Ann Epidemiol 1994;4:369-74.
55. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
56. Meade TW. Factor VII and ischemic heart disease: epidemiological evidence. Haemostasis 1983;13:178-85.
57. Carvalho de Sousa J, Bruckert E, Giral P, et al. Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study. Haemostasis 1989;19:83-90.
58. Hoffman CJ, Miller RH, Lawson WE, Hultin MB. Evaluation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989;14:941-64.
59. Friesewinkel O, Marbet GA, Ritz R. Factor VII und Protein C Marker sind keine prognostischen Indikatoren bei akuter koronarer Herzkrankheit. Schweiz Med Wschr 1993;123:82-4.
60. Jern C, Eriksson E, Tengborn L, Riberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemostas 1989;62:767-71.
61. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. New Engl J Med 1986:315:983-9.
62. Petersen HD, Gormsen J. Platelet aggregation in diabetes mellitus. Acta Med Scand 1978;203:125-30.
63. Verhaeghe R, Piessens J, Suy R, Verstraete M. Platelet survival in patients with angiographically diseased and normal coronary arteries. Thromb Haemostas 1984;52:164-6.
64. Tschöpe D, Lampeter E, Schwippert B. Megakaryocytes and platelets in diabetes mellitus. Hämostaseologie 1996;16:144-50.
65. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl J Med 1996;334:1090-4.